The drug binds endogenous CRBN, resulting in the inhibition of its autoubiquitination and subsequent suppression of interferon regulatory factor 4 (IRF4), which is critical for MM cell survival [178]. This evidence concerns the gene IRF4 and Miyoshi myopathy.